Available now, this new proprietary dispensing capability lets customers order the exact single-use bag sizes and quantities their process requires, released as a single lot with one Certificate of Analysis, with no added turnaround time

HOLLISTER, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) — Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today introduced the Fill-Tek™ Dispensing System. Fill-Tek is a proprietary single-use bag dispensing capability that fills an entire custom reagent order across multiple bag sizes and quantities as a single lot. The Fill-Tek system removes the per-bag-size minimums that come with fixed manifold designs, so manufacturers can order the formats their process calls for rather than the formats the fill line requires.

“Your process is one of a kind, and now your fill line can be, too,” said Stephen Gunstream, President and Chief Executive Officer. “Our new Fill-Tek Dispensing System is the latest evolution of our modular manufacturing platform, expanding our ability to truly meet our customers’ complex custom reagent needs. Previously, fixed manifold designs could constrain the number of single-use bags that could be filled as one lot. Our talented team of engineers developed Fill-Tek to remove that constraint entirely. Following the recent introduction of our AI-driven Build-Tek™ Custom Configurator, the launch of Fill-Tek demonstrates our team’s commitment to continued innovation across the entire custom order process to meet the ever-changing needs of our customers who develop and manufacture emerging therapies and diagnostics.”

With the Fill-Tek Dispensing System, customers can simply specify the various bag sizes and quantities across formats ranging from 250 mL to 200 L single-use bags, and then tailor fill volume, number, size, and sequence of QC samples, testing requirements, and connectors. Fill-Tek uses validated aseptic welds to connect the customer’s specific combination of single-use bags to a dispensing vessel so they can be filled from a single batch through a single filter, resulting in one Certificate of Analysis for each lot.

“The bioprocessing workflows and manufacturing requirements for novel therapeutics and diagnostics are complex and dynamic, and we’re committed to finding better ways to streamline and support them. Fill-Tek operates by formulating and dispensing from one batch vessel through one filter into the exact configurations that a customer may need, including a variety of bag sizes with different fill volumes, or even a single bag,” said Bella Neufeld, Teknova’s Vice President of Operations. “With Fill-Tek, we simplify incoming quality control requirements, enable the use of the same reagent in different volumes at different workflow stages, and minimize rework by attaching the right connectors onto the bags so they seamlessly integrate into an existing bioprocessing system.”

Fill-Tek runs in Teknova’s ISO-classified cleanrooms as part of the Company’s validated aseptic dispensing process, backed by its ISO 13485:2016 certified quality management system. The capability is available across Teknova’s RUO, RUO+, and GMP manufacturing grades, with batch volumes that start from eight liters for custom research-grade orders and 25 liters for GMP-grade orders, scaling up to 2,000 liters – all with no change to Teknova’s industry-leading turnaround times.

Fill-Tek is available today. To place a custom order, customers can use the Build-Tek Custom Configurator on Teknova’s website, email info@teknova.com, or call 1.800.209.4488.

For more information about the Fill-Tek Dispensing System, click here.

ABOUT TEKNOVA

Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in genomics, molecular diagnostics, and emerging therapeutic modalities. Our fast turnaround of high-quality agar plates, microbial culture and cryopreservation media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 180,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of next-generation therapies.

This press release was published by a CLEAR® Verified individual.

CONTACT: CONTACTS

Investor Contact
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100

Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259

Stephen Willard

Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN)
Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN)

Company Announces Exploration of All Options to Maximize Shareholder Value

  • The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular ejection fraction (RVEF) at month 12, but there were exploratory clinical endpoints that the Company is continuing to analyze and plans to discuss with the FDA to determine a potential path forward in HLHS
  • Laromestrocel has maintained what Longeveron believes is a favorable safety and tolerability profile consistent with prior clinical trials, now with 644 patients treated across Longeveron’s multiple clinical programs, and has shown potential efficacy in clinical studies across multiple indications and has received 5 designations from FDA
  • Laromestrocel has shown positive initial results in Aging-related Frailty, including publication of clinical trial results in Cell Stem Cell and selection as a Finalist awardee in the XPRIZE Healthspan global competition
  • The Company has initiated a process of optimizing cost containment and will explore all options with the goal of maximizing shareholder value

MIAMI, Sept. 16, 2026 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced topline results from ELPIS II, its Phase 2b clinical trial evaluating its investigational stem cell therapy laromestrocel as an adjunct to Stage 2 palliative surgery in 40 infants with hypoplastic left heart syndrome (HLHS). The ELPIS II trial did not meet the primary efficacy endpoint of change from baseline in right ventricular ejection fraction (RVEF) at Month 12. In the intent-to-treat (ITT) population, the least-squares mean difference between treatment groups was −0.7 percentage points (95% CI: −7.3 to 5.9; p=0.8336).

Initial exploratory clinical outcomes in the as-treated analyses include:

  • Over a 12-month period, there were no deaths in patients that received laromestrocel, compared to one patient in the control group, in the as-treated group
  • Over a long-term follow up of transplant-free survival (up to five years across all patients), the laromestrocel arm had one event (out of 17 patients) vs. two events (out of 21 patients) in the standard-of-care arm
  • Hospitalization burden was similar between arms
  • Adjudicated Major Adverse Cardiovascular Events (MACE) were approximately 31% fewer in the laromestrocel arm (12 events in the treated arm vs. 19 events in the untreated arm, respectively). However, the negative binomial analysis was not statistically significant.

A sponsor-defined exploratory hierarchical composite endpoint consisting of all-cause mortality and duration of inpatient hospitalization was not statistically significant in the ITT population.

Laromestrocel demonstrated a safety profile generally consistent with prior clinical trials, and no new safety signals were identified in the study.

The Company is conducting additional analyses of the complete dataset and intends to discuss the results with the U.S. Food and Drug Administration (FDA) to determine potential next steps for the HLHS development program. FDA previously indicated its willingness to meet with the Company following completion of the study to discuss the results and potential paths forward.

Sunjay Kaushal, M.D., Ph.D., Professor of Surgery, Cardiovascular and Thoracic Surgery at University of Nevada, Las Vegas commented: “There remains a significant unmet medical need to boost the survival of the babies undergoing standard of care surgeries that still have only a 50-60% survival rate to adolescence with approximately 20% requiring heart transplant. ELPIS II provides evidence of the safety of using stem cells to address this unmet need.”

Laromestrocel demonstrated a favorable safety and tolerability profile in ELPIS II, consistent with the safety experience observed across Longeveron’s clinical development programs, in which 644 participants have been treated to date. Treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TE-SAEs) were reported in 94.1% and 64.7% of laromestrocel-treated participants, respectively, compared with 100% and 71.4% of control participants. No new safety signals were identified, and no TEAEs or TE-SAEs were assessed by investigators as related to laromestrocel.

The Company thanks the patients, families, investigators, and clinical sites who participated in the ELPIS II trial, as well as the NIH and the Data Coordinating and Clinical Coordinating Centers for their partnership throughout the study.

“Since its founding, Longeveron has advanced the stem cell therapy laromestrocel, completed multiple clinical trials and built a robust intellectual property portfolio,” said Stephen H. Willard, Chief Executive Officer of Longeveron. “The ELPIS II results continue to build our body of knowledge of laromestrocel for which we see significant promise across multiple indications, particularly in longevity and Aging-related Frailty. We will work with our advisors to evaluate all options to maximize shareholder value.”

Review of All Options to Maximize Shareholder Value
The Company announced that it has initiated a process to review all options with the goal of maximizing shareholder value. The Company intends to engage an investment bank to act as a strategic advisor for this process. In conjunction with that process, the Company will look to implement cash conservation measures to optimize cost containment.

Longevity and Aging-Related Frailty
The Company intends to pursue funding sources and other potential revenue opportunities to advance laromestrocel in longevity and Aging-related Frailty. Results from a Phase 2b clinical trial demonstrated that intravenous laromestrocel improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo. These results were published in Cell Stem Cell in February 2026. Further, based on these clinical trial results, Longeveron announced in August 2026 that it was selected from over 600 worldwide applicants to advance to the final phase of the XPRIZE Healthspan competition as a Milestone 2 Awardee team. Longeveron received the $1,000,000 Milestone 2 Award to be used towards the future competition clinical trial in accordance with the XPRIZE competition rules, with the opportunity to compete for the XPRIZE Grand Prize of up to $81 million.

Longeveron has been invited to participate in six upcoming longevity focused investor conferences in the fourth quarter of 2026.

About ELPIS II
ELPIS II is a Phase 2b, randomized, double-blind, multicenter, two-arm trial conducted by Longeveron in collaboration with the National Heart, Lung, and Blood Institute (NHLBI) through grants from the National Institutes of Health (NIH) (NCT04925024). A total of 40 infants with HLHS were randomized 1:1 to receive a single intramyocardial dose of laromestrocel administered during Stage 2 palliative surgery (bidirectional Glenn or hemi-Fontan procedure) or standard of care surgery alone, and were followed for 12 months. Long-term follow-up for transplant-free survival is planned for up to 5 years.

The trial’s primary endpoint was the difference between groups’ change from baseline in RVEF at 12 months, assessed by cardiac magnetic resonance (CMR). As previously disclosed, FDA has advised Longeveron that RVEF alone would not be sufficient to demonstrate efficacy for regulatory approval.  FDA also previously expressed willingness to meet with Longeveron when the ongoing study is completed to discuss the study results and align on a potential path forward.

Research reported in this press release was supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Number UH3HL148318. The content is solely the responsibility of the Company and does not necessarily represent the official views of the National Institutes of Health.

About Hypoplastic Left Heart Syndrome (HLHS)
HLHS is a rare congenital heart defect that effects approximately 1,000 infants per year in the U.S. Infants with HLHS are born with an underdeveloped left ventricle, which creates a life-threatening condition due to the heart’s inability to pump adequate amounts of blood throughout the body. The current treatment requires infants to undergo a complex three-stage heart reconstruction surgery process over the first five years of their life. Despite staged surgical palliation, long-term mortality and morbidity remain substantial, with progressive right ventricular dysfunction representing a major contributor to adverse outcomes. There is clearly an important unmet medical need to improve right ventricular function in these infants to positively impact both short- and long-term patient outcomes.

About laromestrocel (Lomecel-B®)
Laromestrocel is a living cell product made from specialized cells isolated from the bone marrow of young, healthy adult donors. These specialized cells, known as mesenchymal stem cells (MSCs), are essential to the human endogenous biological repair mechanism. MSCs have the potential to perform a number of complex functions in the body and possibly support tissue repair and regenerative signaling pathways. They also may respond to sites of injury or disease and may secrete bioactive factors that are immunomodulatory and regenerative. We believe laromestrocel MSCs may have multiple potential mechanisms of action that may lead to anti-inflammatory, pro-vascular regenerative responses, and therefore may have broad application for a range of rare and aging related diseases.

About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. We believe laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, Pediatric Dilated Cardiomyopathy (DCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program – Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program – Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve known and unknown risks, uncertainties, and other important factors that could cause actual results, performance, or achievements to differ materially from those anticipated, expressed, or implied by the statements made herein. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including discussion of ELPIS II results with the FDA and the future of the HLHS development program; our ability to pursue funding sources and potential revenue opportunities to advance laromestrocel in longevity and Aging-related frailty; our expectations regarding the review and exploration of all options and their potential impact on shareholder value; our ability to engage an investment bank or other strategic advisor; the continued listing of our Class A common stock on Nasdaq; our expectations regarding the future of the company’s operations, including our clinical, development and commercialization activities; our plans to implement cash conservation measures to reduce operating expenses; and other statements regarding future events. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expects,” “intend,” “looks to,” “may,” “on condition,” “plan,” “potential,” “predict,” “preliminary,” “project,” “see,”  “should,” “target,” “will,” “would,” or the negative thereof or comparable terminology, although not all forward-looking statements contain these words, or by discussion of strategy or goals or other future events, circumstances, or effects. Additional factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, the risk that the exploration of strategic options may not result in any definitive transaction or enhance shareholder value or may create uncertainty that may adversely affect our business, financial condition, results of operations, or shareholder and investor perception; the ability of our clinical trials to demonstrate safety and efficacy of our investigational product candidates, and other positive results; our ability to successfully transition toward a more capital-efficient, asset-light operating model; our ability to secure one or more strategic licensing partnerships for laromestrocel in our development programs; our ability to reach alignment with the FDA and other regulatory authorities on a potential path toward regulatory approval; the availability of evidence from our ongoing and future preclinical studies and clinical trials sufficient to support the Company filing a BLA for the investigational product candidate for one or more indications; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; market and other conditions, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements;  the size of the market opportunity for certain of our investigational product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to scale production and commercialize the investigational product candidate for certain indications; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our investigational product candidates; our ability to obtain and maintain regulatory approval of our investigational product candidates in the U.S. and other jurisdictions; our plans relating to the further development of our investigational product candidates, including additional disease states or indications we may pursue; our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 17, 2026, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. The Company operates in a highly competitive and rapidly changing environment; therefore, new factors may arise, and it is not possible for the Company’s management to predict all such factors that may arise nor assess the impact of such factors or the extent to which any individual factor or combination thereof, may cause results to differ materially from those contained in any forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release based on information available as of the date of this press release, are inherently uncertain, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor and Media Inquiries:
investorrelations@longeveron.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/cde71c09-a5f1-424d-837b-80f8786d82a5

XTEND selected as a Gauntlet II leader in the Close Quarters Battle segment following successful delivery and demonstration of 120 STRIKER systems

TAMPA, Fla., Sept. 16, 2026 (GLOBE NEWSWIRE) — XTEND AI Robotics, Inc. (NYSE: XTND) today announced that it was selected as a top performer in the close quarters battle segment of Gauntlet II of the U.S. Department of War’s iterative $1 billion Drone Dominance Program (DDP).

The result follows XTEND’s successful delivery and demonstration of 120 STRIKER systems in operationally realistic scenarios evaluated by warfighters for Gauntlet II, and marks another significant milestone in the company’s growing role in U.S. defense programs.

“This is a major win for XTEND,” said Aviv Shapira, Co-Founder and CEO of XTEND. “We delivered, we competed, and we proved what STRIKER is capable of in the hands of U.S. warfighters. This achievement demonstrates the strength of our technology.”

STRIKER is powered by XTEND’s proprietary XOS operating system and is designed for tactical missions in confined, complex and GNSS-denied environments.

The $1 billion U.S. Department of War Drone Dominance Program is building a resilient, U.S.-based supply chain for low-cost, capable one-way attack drone systems, jointly managed by the Defense Innovation Unit (DIU) and the Test Resource Management Center (TRMC). Naval Surface Warfare Center, Crane Division (NSWC Crane) serves as the DDP contracting authority.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the capabilities of XOS and its STRIKER system and its financial prospects, including that according to the Drone Dominance Program the 10 companies selected for Gauntlet II are finalists for prototype contracts and awards are not guaranteed. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially, including the timing and size of orders from government and defense customers, geopolitical and economic conditions in the United States and the other regions in which XTEND operates, and the other risks described under “Risk Factors” in the registration statement on Form S-4 filed with the SEC in connection with the business combination and in XTEND’s other filings with the SEC, available at www.sec.gov. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. XTEND does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by applicable law.

About XTEND AI Robotics, Inc.

XTEND is a leader in software systems and Physical AI, deployed in high-threat, complex operational environments where human exposure carries significant risk. Powered by its proprietary XTEND Operating System (XOS), XTEND’s integrated software and advanced robotic hardware solutions are designed to provide autonomy at the edge. Operating across Defense, Homeland Security, and Commercial Security missions through a platform of robots, drones, and robotic subsystems, XTEND’s open architecture platform facilitates scalability across partners and third-party applications. With over 12,500 systems deployed in over 30 countries, XTEND’s solutions have been validated in five combat zones and operationally deployed by national defense, special-mission units, and security organizations across the globe. Founded in Tel Aviv, Israel, and headquartered in Tampa, Florida, XTEND delivers NDAA-compliant solutions through a global network of regional XFAB manufacturing facilities located in the U.S., the U.K., Singapore, Israel, Mexico and Latvia.

Contacts
XTEND Media Contact:
Headline Media
Sarah Small
929-255-1449
sarah@headline.media

XTEND Investor Relations:
MZ North America
Shannon Devine
203-741-8811
XTND@mzgroup.us

LOS ANGELES, Sept. 16, 2026 (GLOBE NEWSWIRE) — Preferred Bank (NASDAQ: PFBC), one of the larger independent commercial banks in California, today reported that the Board of Directors has declared a quarterly cash dividend of $0.80 per share, payable on October 19, 2026 to holders of record on October 5, 2026.

About Preferred Bank

Preferred Bank is one of the larger independent commercial banks headquartered in California. The Bank is chartered by the State of California, and its deposits are insured by the Federal Deposit Insurance Corporation, or FDIC, to the maximum extent permitted by law. The Bank conducts its banking business from its main office in Los Angeles, California, and through thirteen full-service branch banking offices in California (Alhambra, Century City, City of Industry, Torrance, Arcadia, Irvine (2), Diamond Bar, Pico Rivera, Tarzana and San Francisco (2)), Cupertino, two branches in New York (Manhattan and Flushing, Queens) and a branch office in the Houston, Texas suburb of Sugar Land. Preferred Bank offers a broad range of deposit and loan products and services to both commercial and consumer customers. The Bank provides personalized deposit services as well as real estate finance, commercial loans and trade finance to small and mid-sized businesses, entrepreneurs, real estate developers, professionals and high net worth individuals. Although originally founded as a Chinese-American Bank, Preferred Bank now derives most of its customers from the diversified mainstream market but does continue to benefit from the significant migration to California of ethnic Chinese from China and other areas of East Asia.

AT THE COMPANY: AT FINANCIAL PROFILES:
Edward J. Czajka Jeffrey Haas
Executive Vice President General Information
Chief Financial Officer (310) 622-8221
(213) 891-1188 PFBC@finprofiles.com
   

Ontario, CA, Sept. 16, 2026 (GLOBE NEWSWIRE) — CVB Financial Corp. (NASDAQ: CVBF) (the “Company”) announced a twenty cent ($0.20) per share cash dividend with respect to the third quarter of 2026. This dividend was approved at the Company’s regularly scheduled Board of Directors meeting held on September 16, 2026. The quarterly dividend will be payable on or about October 15, 2026, to shareholders of record as of September 30, 2026.

“Our consistent and strong financial performance has enabled the Bank to announce our 148th consecutive quarterly cash dividend to be paid to our shareholders” said David A. Brager, Chief Executive Officer.

Corporate Overview
CVB Financial Corp. (“CVBF”) is the holding company for Citizens Business Bank, National Association. CVBF is one of the 10 largest bank holding companies headquartered in California with more than $20 billion in total assets. Citizens Business Bank, National Association, is consistently recognized as one of the top performing banks in the nation and offers a wide array of banking, lending and investing services, with more than 75 banking centers and three trust office locations serving California.

Shares of CVB Financial Corp. common stock are listed on the NASDAQ under the ticker symbol “CVBF”. For investor information on CVBF, visit our Citizens Business Bank website at www.cbbank.com and click on the “Investors” tab.

Safe Harbor
Certain matters set forth herein may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including forward-looking statements relating to the Company’s current business plans and expectations, growth projections, and our future financial position and operating results. Words such as “will likely result, “aims”, “anticipates”, “believes”, “could”, “estimates”, “expects”, “hopes”, “intends”, “may”, “plans”, “projects”, “seeks”, “should”, “will” and variations of these words and similar expressions help to identify these forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results, performance and/or achievements to differ materially from those projected. These risks and uncertainties include, but are not limited to, all the risk factors set forth in the Company’s public reports, including its Annual Report on Form 10-K for the year ended December 31, 2025, and particularly the discussion of risk factors within that document. The Company does not undertake, and specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences or unanticipated events or circumstances after the date of such statements except as required by law.

Contact: David A. Brager
Chief Executive Officer
(909) 980-4030

Jeanne Boillet Photo

MONTRÉAL, Sept. 16, 2026 (GLOBE NEWSWIRE) — Bombardier is pleased to announce the appointment of Ms. Jeanne Boillet to its Board of Directors, effective October 1, 2026.

Jeanne Boillet brings more than four decades of international experience in audit, governance, innovation and business transformation. She recently retired from EY after a distinguished career spanning France and Switzerland, where she served as Lead Audit Partner for some of the most prominent companies in the CAC 40 and the Swiss Market Index (SMI).

Throughout her career, Ms. Boillet held numerous leadership positions at the national, regional and global levels. As a member of EY’s Global Assurance Executive Leadership Team and Global Account Committee, she played a key role in shaping strategy and driving innovation across the organization. From 2015 to 2020, she led EY Global Assurance’s innovation agenda, advancing the adoption of analytics, artificial intelligence and blockchain technologies and overseeing the integration of AI into the firm’s audit platforms.

Most recently, Ms. Boillet led EY’s global community of audit partners serving the firm’s 35 largest audit clients worldwide. In this role, she helped shape the future of the audit profession, define strategic priorities and strengthen the profession’s value proposition for clients, boards of directors, investors and other stakeholders.

“Jeanne brings exceptional experience in governance, technology-enabled transformation and stakeholder engagement, gained through decades of advising leading global organizations,” said Pierre Beaudoin, Chairman of the Board, Bombardier. “Her international perspective, deep understanding of complex businesses and commitment to innovation will be invaluable as Bombardier continues to execute its strategy and build on its leadership position in business aviation.”

A recognized thought leader, Ms. Boillet has authored numerous articles on the future of audit, the impact of emerging technologies and the evolution of corporate governance. She is a Certified Public Accountant in both France and Switzerland and holds an MBA in Accounting and Finance from ESSEC Business School. She has also completed the EY Sustainable Finance Programme at INSEAD and the EY Journey to the Boardroom Program at Harvard Business School Executive Education.

“I am honored and delighted to join Bombardier’s Board of Directors at such an exciting time in the company’s evolution,” said Jeanne Boillet. “Bombardier’s successful transformation, strong competitive position and ambitious vision for the future make this a unique moment in the company’s journey. Throughout my career, I have worked with global organizations navigating transformation, technological change and increasing stakeholder expectations. I look forward to bringing that experience to the Board and working alongside my fellow directors and the management team to support Bombardier’s continued growth, innovation and long-term value creation.”

About Bombardier

At Bombardier (BBD-B.TO), we design, build, modify and maintain the world’s best-performing aircraft for the world’s most discerning people and businesses, governments and militaries. That means not simply exceeding standards, but understanding customers well enough to anticipate their unspoken needs.

For them, we are committed to pioneering the future of aviation—innovating to make flying more reliable, efficient and sustainable. And we are passionate about delivering unrivaled craftsmanship and care, giving our customers greater confidence and the elevated experience they deserve and expect. Because people who shape the world will always need the most productive and responsible ways to move through it.

Bombardier customers operate a fleet of more than 5,200 aircraft, supported by a vast network of Bombardier team members worldwide and 10 service facilities across six countries. Bombardier’s performance-leading jets are proudly manufactured in aerostructure, assembly and completion facilities in Canada, the United States and Mexico. In 2024, Bombardier was honoured with the prestigious “Red Dot: Best of the Best” award for Brands and Communication Design.

For Information

For corporate news and information, including Bombardier’s Sustainability report, as well as the company’s initiative to cover all its flight operations with a Sustainable Aviation Fuel (SAF) blend utilizing the Book-and-Claim system visit bombardier.com.

Learn more about Bombardier’s industry-leading products and customer service network at bombardier.com. Follow us on X @Bombardier.

Media Contacts
General media contact webform

Francis Richer de La Flèche  
Vice President, Financial Planning and Investor Relations 
Bombardier 
+1 514 240-9649

Mark Masluch 
Senior Director, Communications 
Bombardier 
+1 514 855-7167

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/22802860-90e6-4bc5-be68-595c8276c2d4

SKOKIE, Ill., Sept. 16, 2026 (GLOBE NEWSWIRE) — LanzaTech Global, Inc. (NASDAQ: LNZA) (“LanzaTech” or the “Company”), a carbon management solutions company, today announced that was featured on the Water Tower Research Small-Cap Spotlight. The event was hosted by Tim Gerdeman, Co-Founder of Water Tower Research.

The conversation provides investors with a detailed look at:

  • LanzaTech’s biofermentation technology, and its proprietary processes which turn industrial waste gas into ethanol for sustainable aviation fuel, marine fuel, and chemicals, targeting a multi-trillion dollar global market
  • How LanzaTech is shifting its business model and strategic focus from pure licensing to owning and operating its own projects, backed by $500M+ from Brookfield.
  • How recent European certification is expected to open higher-value EU/UK market opportunities and create significant market demand
  • LanzaTech’s key milestones it expects to achieve over the next 12–18 months, including the first Brookfield project transfer, FID/construction launches on UK and Belgium projects, and initial marine-fuel use of its recycled carbon ethanol.

A link to the webcast of the LanzaTech Global Inc.’s presentation will be available on the Company’s Investor Relations website ir.lanzatech.com under the Events & Presentations section, beginning September 16, 2026. The podcast interview will also be available on the Water Tower Research YouTube page.

About LanzaTech

LanzaTech (NASDAQ: LNZA) is a leader in carbon management, using its proprietary gas-fermentation platform to transform waste carbon into valuable products. Through global partnerships, LanzaTech enables the production of feedstocks for high-value markets including SAF and chemicals. Headquartered in the U.S., the company provides technology and commercial pathways that strengthen industrial resilience and unlock new economic value from carbon.

Forward-Looking Statements

This press release includes forward-looking statements regarding, among other things, the plans, strategies and prospects, both business and financial, of the Company. These statements are based on the beliefs and assumptions of the Company’s management. Although the Company believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, the Company cannot assure you that it will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or results of operations, are forward-looking statements. These statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “will,” “should,” “seeks,” “plans,” “scheduled,” “anticipates,” “intends” or similar expressions. The forward-looking statements are based on projections prepared by, and are the responsibility of, the Company’s management. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements, including the Company’s ability to continue operations as a going concern; the Company’s ability to attract new investors and raise substantial additional financing to fund its operations and/or execute on its other strategic options; delays or interruptions in government contract awards, funding cycles or agency operations (including due to a government shutdown) that could postpone project milestones and defer related revenue recognition; the Company’s ability to maintain the listing of the Nasdaq Stock Market LLC; the Company’s ability to execute on its business strategy and achieve profitability; its securities on the Company’s ability to attract, retain and motivate qualified personnel, the Company’s anticipated growth rate and market opportunities; the potential liquidity and trading of the Company’s securities; the Company’s future financial performance and capital requirements; the Company’s assessment of the competitive landscape; the Company’s ability to comply with laws and regulations applicable to its business; the Company’s ability to enter into, successfully maintain and manage relationships with industry partners; the availability of governmental programs designed to incentivize the production and consumption of low-carbon fuels and carbon capture and utilization; the Company’s ability to adequately protect its intellectual property rights; the Company’s ability to manage its growth effectively; the Company’s ability to increase its revenue from engineering services, sales of equipment packages and sales of CarbonSmart products and to improve its operating results; and the Company’s ability to remediate the material weaknesses in its internal control over financial reporting and to maintain effective internal controls. The Company may be adversely affected by other economic, business, or competitive factors, and other risks and uncertainties, including those described under the header “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2025 and in future SEC filings. New risk factors that may affect actual results or outcomes emerge from time to time and it is not possible to predict all such risk factors, nor can the Company assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. The Company undertakes no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations Contact:
LNZA@alpha-ir.com

Public Relations/Media Contact:
Freya Burton
freya@lanzatech.com

CALGARY, Alberta, Sept. 16, 2026 (GLOBE NEWSWIRE) — This news release contains “forward-looking information and statements” within the meaning of applicable securities laws. For a full disclosure of the forward-looking information and statements and the risks to which they are subject, see the “Cautionary Statement Regarding Forward-Looking Information and Statements” later in this news release.

Precision Drilling Corporation (Precision or the Company) (TSX: PD; NYSE: PDS) announced today that the Toronto Stock Exchange (the TSX) has approved its intention to implement a Normal Course Issuer Bid (NCIB) for a portion of its Common Shares (Common Shares). Precision believes the NCIB continues to represent another tool for the Company to enhance the value of its underlying shares.

Pursuant to the renewed NCIB, the Company has been authorized by the TSX to acquire up to a maximum of 1,229,799 Common Shares, or approximately 10% of the public float as of September 8, 2026, for cancellation. As of September 8, 2026, Precision had 12,587,470 Common Shares issued and outstanding and a public float of 12,297,993 Common Shares. Purchases under the NCIB may commence on September 21, 2026 and will terminate no later than September 20, 2027, or such earlier time as the Company completes its purchases pursuant to the NCIB or provides notice of termination.

Purchases under the NCIB will be made in accordance with applicable regulatory requirements through the facilities of the TSX, the New York Stock Exchange (the NYSE), other designated exchanges and/or alternative trading systems in Canada or the United States or by such other means as may be permitted by the applicable securities regulator at a price per Common Share representative of the market price at the time of acquisition. The number of Common Shares that can be purchased pursuant to the NCIB is subject to a current daily maximum of 22,165 Common Shares (which is equal to 25% of the average daily trading volume of 88,661 Common Shares on the TSX for the six full calendar months ending August 31, 2026), subject to the Company’s ability to make one block purchase of Common Shares per calendar week that exceeds such limits. All Common Shares purchased under the NCIB will be cancelled after their purchase. The Company intends to fund the purchases out of its available resources.

Pursuant to its prior NCIB, under which the Company had approval from the TSX to purchase up to 1,251,850 Common Shares for the period of September 19, 2025 to September 18, 2026, through September 8, 2026 the Company has purchased 668,674 Common Shares on the TSX, NYSE and alternative trading systems at a weighted average purchase price of CAD$102.54 per Common Share.

The Company intends to enter into an automatic securities purchase plan effective September 21, 2026 under which its broker may purchase Common Shares in connection with the NCIB. The plan will contain a prearranged set of criteria in accordance with which its broker may make Common Share purchases. These strict parameters enable the purchase of Common Shares during times when it would ordinarily not be permitted due to self-imposed blackout periods, insider trading rules or otherwise. Such plan is adopted in accordance with applicable Canadian securities laws and the requirements of Rule 10b5-1 under the U.S. Securities Exchange Act of 1934, as amended.

About Precision

Precision is a leading provider of safe and environmentally responsible High Performance, High Value services to the energy industry, offering customers access to an extensive fleet of Super Series drilling rigs. Precision has commercialized an industry-leading digital technology portfolio known as Alpha™ that utilizes advanced automation software and analytics to generate efficient, predictable, and repeatable results for energy customers. Our drilling services are enhanced by our EverGreen™ suite of environmental solutions, which bolsters our commitment to reducing the environmental impact of our operations. Additionally, Precision offers well service rigs, camps and rental equipment all backed by a comprehensive mix of technical support services and skilled, experienced personnel.

Precision is headquartered in Calgary, Alberta, Canada and is listed on the Toronto Stock Exchange under the trading symbol “PD” and on the New York Stock Exchange and NYSE Texas, Inc., under the trading symbol “PDS”.

Cautionary Statement Regarding Forward-Looking Information and Statements

Certain statements contained in this release, including statements that contain words such as “could”, “should”, “can”, “anticipate”, “estimate”, “intend”, “plan”, “expect”, “believe”, “will”, “may”, “continue”, “project”, “potential” and similar expressions and statements relating to matters that are not historical facts constitute “forward-looking information” within the meaning of applicable Canadian securities legislation and “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 (collectively, “forward-looking information and statements”).

In particular, forward-looking information and statements include, but are not limited to the funding of purchases under the NCIB and the entering into of an automatic securities purchase plan and advantages of the NCIB.

These forward-looking information and statements are based on certain assumptions and analysis made by Precision in light of our experience and our perception of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances. These include, among other things:

  • the fluctuation in oil prices may pressure customers into reducing or limiting their drilling budgets;
  • the status of current negotiations with our customers and vendors;
  • customer focus on safety performance;
  • existing term contracts are neither renewed nor terminated prematurely;
  • continued market demand for Super Spec rigs;
  • our ability to deliver rigs to customers on a timely basis;
  • the impact of climate change on our business;
  • the general stability of the economic and political environments in the jurisdictions where we operate; and
  • the impact of an increase/decrease in capital spending.

Undue reliance should not be placed on forward-looking information and statements. Whether actual results, performance or achievements will conform to our expectations and predictions is subject to a number of known and unknown risks and uncertainties which could cause actual results to differ materially from our expectations. Such risks and uncertainties include, but are not limited to:

  • volatility in the price and demand for oil and natural gas;
  • fluctuations in the level of oil and natural gas exploration and development activities;
  • fluctuations in the demand for contract drilling, well servicing and ancillary oilfield services;
  • our customers’ inability to obtain adequate credit or financing to support their drilling and production activity;
  • changes in drilling and well servicing technology, which could reduce demand for certain rigs or put us at a competitive advantage;
  • shortages, delays and interruptions in the delivery of equipment supplies and other key inputs;
  • liquidity of the capital markets to fund customer drilling programs;
  • availability of cash flow, debt and equity sources to fund our capital and operating requirements, as needed;
  • the impact of weather and seasonal conditions on operations and facilities;
  • the impact of tariffs and trade disputes;
  • competitive operating risks inherent in contract drilling, well servicing and ancillary oilfield services;
  • ability to improve our rig technology to improve drilling efficiency;
  • public health crises that impact demand for our services and our business;
  • general economic, market or business conditions;
  • the availability of qualified personnel and management;
  • a decline in our safety performance which could result in lower demand for our services;
  • business interruptions related to cybersecurity risks;
  • changes in laws or regulations, including changes in environmental laws and regulations such as increased regulation of hydraulic fracturing or restrictions on the burning of fossil fuels and greenhouse gas emissions, which could have an adverse impact on the demand for oil and natural gas;
  • terrorism, social, civil and political unrest in the foreign jurisdictions where we operate;
  • fluctuations in foreign exchange, interest rates and tax rates; and
  • other unforeseen conditions which could impact the use of services supplied by Precision and Precision’s ability to respond to such conditions.

Readers are cautioned that the foregoing list of risk factors is not exhaustive. Additional information on these and other factors that could affect our business, operations or financial results are included in reports on file with applicable securities regulatory authorities, including but not limited to Precision’s Annual Information Form for the year ended December 31, 2025, which may be accessed on Precision’s SEDAR+ profile at www.sedarplus.ca or under Precision’s EDGAR profile at www.sec.gov. The forward-looking information and statements contained in this news release are made as of the date hereof and Precision undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, except as required by law.

Additional Information

For further information about Precision, please visit our website at www.precisiondrilling.com or contact:

Lavonne Zdunich, CPA, CA
Vice President, Investor Relations
403.716.4500

800, 525 – 8th Avenue S.W.
Calgary, Alberta, Canada T2P 1G1
Website: www.precisiondrilling.com

New York, NY, Sept. 16, 2026 (GLOBE NEWSWIRE) — Churchill Capital Corp XIII (Nasdaq: XIIIU) (the “Company”) announced today that, commencing September 18, 2026, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The Class A ordinary shares and warrants that are separated will trade on the Nasdaq Global Market under the symbols “XIII” and “XIIIW,” respectively. Those units not separated will continue to trade on the Nasdaq Global Market under the symbol “XIIIU.”

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Churchill Capital Corp XIII

Churchill Capital Corp XIII was founded by Michael Klein, who is also the founder and managing partner of M. Klein and Company, LLC. The Company was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It may pursue an initial business combination target in any business or industry.

Forward-Looking Statements

This press release may include, and oral statements made from time to time by representatives of the Company may include, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding possible business combinations and the financing thereof, and related matters, as well as all other statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company’s filings with the Securities and Exchange Commission (“SEC”). All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus for the Company’s initial public offering filed with the SEC. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Company Contact

Churchill Capital Corp XIII
info@churchillcapitalcorp.com
212-380-7500

HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) — Targa Resources Corp. (NYSE: TRGP) (“Targa”, the “Company”, or “our”) announced today that our Sustainability Report for 2025 is now available on the Company’s website at https://www.targaresources.com/sustainability. The report provides a review of our performance for calendar year 2025 against various environmental, social, and governance topics that Targa believes are important to the industry and the Company’s business.

About Targa Resources Corp.

Targa Resources Corp. is a leading provider of midstream services and is one of the largest independent infrastructure companies in North America. The Company owns, operates, acquires and develops a diversified portfolio of complementary domestic infrastructure assets and its operations are critical to the efficient, safe and reliable delivery of energy across the United States and increasingly to the world. The Company’s assets connect natural gas and NGLs to domestic and international markets with growing demand for cleaner fuels and feedstocks.

Targa is a FORTUNE 500 company and is included in the S&P 500.

For more information, please visit the Company’s website at www.targaresources.com.

Targa Investor Relations
InvestorRelations@targaresources.com
(713) 584-1133

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.